Drugs / Phenylalanine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03788343 | Aug 2019 → Jun 2022 | phenylketonuria | Insel Gruppe AG, University Hospital Bern | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Phenylalanine | “The study product Phenylalanine, a dietary supplement, is authorized in Switzerland, but not designated for this patient group.” NCT03788343 ↗ |
| Known as | Phe | “Phenylketonuria (PKU) is a rare inborn error of metabolism characterized by impaired catabolism of the amino acid phenylalanine (Phe) into tyrosine.” PMID 39146838 ↗ Aug 2024 |
| Route | Oral | “The cross-over intervention consists of 4-week oral Phe or placebo administration in patients with PKU.” PMID 32054509 ↗ Feb 2020 |